CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: UGGT1 (ImmuneEditome ID:56886)

1. Gene summary of enriched editing regions for UGGT1

check button Gene summary
Gene informationGene symbol

UGGT1

Gene ID

56886

GeneSynonymsHUGT1|UGCGL1|UGT1
GeneCytomap

2q14.3

GeneTypeprotein-coding
GeneDescriptionUDP-glucose:glycoprotein glucosyltransferase 1|UDP--Glc:glycoprotein glucosyltransferase|UDP-glucose ceramide glucosyltransferase-like 1
GeneModificationdate20230329
UniprotIDQ9NYU2;E2QRN8;F8WCI2;F8WCE6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:128191555-128191830:+ENST00000259253.9ENSG00000136731.11UGGT1UTR3AluSgchr2:128191555-128191830:+.alignment
chr2:128192856-128195153:+ENST00000259253.9ENSG00000136731.11UGGT1UTR3AluSp,AluSx1,AluSc,AluSxchr2:128192856-128195153:+.alignment


Top

2. Tumor-specific enriched editing regions for UGGT1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:128192856-128195153:+BRCAEER1.0241e-09image
ENSG00000136731.11,UGGT1BRCAEAG6.7568e-10image
chr2:128192856-128195153:+KICHEER2.2370e-02image
ENSG00000136731.11,UGGT1KICHEAG4.0643e-02image
chr2:128192856-128195153:+KIRCEER2.5513e-03image
ENSG00000136731.11,UGGT1KIRCEAG1.1246e-03image
chr2:128192856-128195153:+LUADEER2.5685e-03image
ENSG00000136731.11,UGGT1LUADEAG1.2499e-03image
chr2:128192856-128195153:+LUSCEER3.3723e-04image
ENSG00000136731.11,UGGT1LUSCEAG2.2006e-04image
chr2:128192856-128195153:+THCAEER3.6968e-02image
ENSG00000136731.11,UGGT1THCAEAG2.6802e-02image
chr2:128192856-128195153:+UCECEER2.7092e-03image
ENSG00000136731.11,UGGT1UCECEAG2.7115e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000136731.11,UGGT1LIHCPathEAG2.2350e-022.6958e-030.1618image
chr2:128192856-128195153:+LIHCPathEER2.7094e-023.3797e-030.1581image
chr2:128192856-128195153:+READPathEER4.1777e-037.7276e-04-0.2708image
ENSG00000136731.11,UGGT1READPathEAG8.6713e-032.0155e-03-0.2494image
chr2:128192856-128195153:+UVMCliEER1.6479e-029.1393e-030.3210image
ENSG00000136731.11,UGGT1UVMCliEAG1.5836e-028.9792e-030.3217image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr2:128192856-128195153:+COADEER1.8497e-027.9381e-031.1897e+01image
ENSG00000136731.11,UGGT1COADEAG1.4235e-021.9193e-029.9112e+00image
chr2:128192856-128195153:+KICHEER1.7031e-022.5268e-021.4415e-21image
ENSG00000136731.11,UGGT1KICHEAG1.7031e-022.8983e-022.4839e-23image
chr2:128192856-128195153:+LIHCEER5.1331e-034.4941e-032.8494e-02image
ENSG00000136731.11,UGGT1LIHCEAG8.0784e-032.2777e-031.9738e-02image
chr2:128191555-128191830:+SKCMEER2.8182e-044.5016e-034.2738e+09image

Top

3. Enriched editing regions and immune related genes for UGGT1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:128192856-128195153:+COADEERENSG00000220205,VAMP20.27714.8957e-043.0055e-210.5308imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr2:128192856-128195153:+COADEERENSG00000116731,PRDM20.23434.8435e-031.9726e-150.4561imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NAEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:128192856-128195153:+COADEERENSG00000252516,RNA5SP820.21927.6483e-038.6594e-130.4150imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:128192856-128195153:+COADEERENSG00000230953,RP4-631H13.60.19742.2723e-025.0004e-140.4350imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:128192856-128195153:+COADEERENSG00000177464,GPR40.18143.9715e-021.1261e-140.4449imageNEIF4A3;ELAVL1;FBLNANeutrophilsGSVA_HALLMARK_ANGIOGENESIS
chr2:128192856-128195153:+COADEERENSG00000179954,SSC5D0.17604.4331e-023.3784e-130.4217imageNEIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr2:128192856-128195153:+GBMEERENSG00000257907,EEF1A1P170.25043.3727e-022.7710e-090.4445imageNNNANK_cells_activatedGSVA_HALLMARK_KRAS_SIGNALING_DN
chr2:128192856-128195153:+GBMEERENSG00000223822,EEF1A1P10.24933.5054e-025.3987e-080.4102imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_MYC_TARGETS_V1
chr2:128192856-128195153:+GBMEERENSG00000268222,EEF1A1P70.23514.7636e-021.2140e-070.4001imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr2:128192856-128195153:+UCECEERENSG00000198783,ZNF830-0.39562.2952e-041.1439e-08-0.4149imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NAT_cells_follicular_helperGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for UGGT1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:128192856-128195153:+
COADEERMEXENSG00000137500.5chr1183265915:83265979:83273646:83273738:83273792:83273864:83273950:83273992-0.21783.7873e-029.0028e-16-0.4610imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NADendritic_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:128192856-128195153:+
COADEERIRENSG00000145247.7chr448897165:48897224:48897803:488978350.21643.8292e-026.3990e-210.5347imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr2:128192856-128195153:+
COADEERMEXENSG00000104960.11chr1949854651:49854734:49854830:49854888:49858056:49858114:49858548:498586370.26065.0977e-034.2289e-180.4951imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NANK_cells_activatedGSVA_HALLMARK_UV_RESPONSE_DN
chr2:128192856-128195153:+
COADEERMEXENSG00000109736.10chr42931102:2931150:2931226:2931274:2931554:2931663:2931824:2931936-0.22612.5973e-024.8784e-12-0.4043imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2MFSD10EosinophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000136731.11,UGGT1
COADEAGMEXENSG00000164692.13chr794412583:94412682:94413082:94413136:94418498:94418552:94419497:944195510.25638.2590e-035.1410e-140.4348imageNADAR;DDX3X;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FUS;HNRNPL;IGF2BP2;LIN28A;MSI1;NOP56;RBFOX2;SND1;TAF15;TARDBP;UPF1COL1A2EosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:128192856-128195153:+
COADEERMEXENSG00000159352.11chr1151265165:151265234:151265393:151265532:151266003:151266112:151266307:1512664390.23821.5789e-022.0228e-130.4253imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2PSMD4EosinophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000136731.11,UGGT1
COADEAGMEXENSG00000159352.11chr1151265165:151265234:151265393:151265532:151266003:151266112:151266307:1512664390.25318.6945e-031.0773e-130.4297imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184PSMD4EosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:128192856-128195153:+
COADEERMEXENSG00000164692.13chr794412583:94412682:94413082:94413136:94418498:94418552:94419497:944195510.25477.4926e-031.3918e-140.4435imageNEIF4A3;ELAVL1;NOP56;RBFOX2COL1A2EosinophilsGSVA_HALLMARK_DNA_REPAIR
chr2:128192856-128195153:+
COADEERIRENSG00000258890.2chr1764530925:64533008:64533116:645331910.20854.7545e-021.1615e-300.6232imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr2:128192856-128195153:+
COADEERESENSG00000170791.13chr856211809:56211837:56212761:56212909:56214597:562146670.22253.0121e-023.3521e-140.4413imageNDDX54;EIF4A3;ELAVL1;FBL;NOP56;NOP58;RBFOX2NAGSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for UGGT1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:128192856-128195153:+ACCEERB_cells_naive1.1257e-020.3149image
ENSG00000136731.11,UGGT1ACCEAGB_cells_naive1.2617e-020.3078image
chr2:128192856-128195153:+BLCAEERB_cells_memory2.3422e-020.1142image
ENSG00000136731.11,UGGT1BLCAEAGB_cells_memory2.5690e-020.1124image
chr2:128192856-128195153:+BRCAEERNK_cells_activated2.5996e-030.0916image
ENSG00000136731.11,UGGT1BRCAEAGNK_cells_activated4.2400e-040.1070image
chr2:128192856-128195153:+CESCEERMonocytes1.7037e-040.2161image
ENSG00000136731.11,UGGT1CESCEAGMonocytes1.5547e-040.2174image
chr2:128192856-128195153:+CHOLEERT_cells_gamma_delta3.9431e-020.3498image
ENSG00000136731.11,UGGT1CHOLEAGT_cells_gamma_delta3.9140e-020.3502image
chr2:128192856-128195153:+COADEEREosinophils1.2025e-040.2307image
ENSG00000136731.11,UGGT1COADEAGEosinophils1.5467e-040.2270image
chr2:128192856-128195153:+DLBCEERT_cells_CD81.5855e-03-0.4437image
ENSG00000136731.11,UGGT1DLBCEAGT_cells_CD81.4157e-03-0.4478image
chr2:128192856-128195153:+ESCAEERMacrophages_M21.3044e-030.2513image
ENSG00000136731.11,UGGT1ESCAEAGT_cells_CD4_memory_resting5.9764e-04-0.2677image
chr2:128192856-128195153:+GBMEERMacrophages_M01.6417e-02-0.1877image
ENSG00000136731.11,UGGT1GBMEAGPlasma_cells1.8255e-02-0.1847image
chr2:128191555-128191830:+HNSCEERT_cells_gamma_delta1.9453e-020.2267image
chr2:128192856-128195153:+HNSCEERNK_cells_activated3.5267e-02-0.0949image
ENSG00000136731.11,UGGT1HNSCEAGT_cells_gamma_delta1.9377e-020.1053image
chr2:128192856-128195153:+KICHEERT_cells_regulatory_(Tregs)9.9492e-03-0.3225image
ENSG00000136731.11,UGGT1KICHEAGT_cells_regulatory_(Tregs)1.1623e-02-0.3161image
chr2:128192856-128195153:+KIRCEERMast_cells_resting3.4320e-020.1086image
ENSG00000136731.11,UGGT1KIRCEAGMast_cells_resting3.8090e-020.1064image
chr2:128192856-128195153:+KIRPEERNK_cells_activated3.3684e-030.1731image
ENSG00000136731.11,UGGT1KIRPEAGNK_cells_activated2.3639e-030.1794image
chr2:128192856-128195153:+LAMLEERB_cells_naive7.2859e-03-0.2205image
ENSG00000136731.11,UGGT1LAMLEAGB_cells_naive1.1641e-02-0.2076image
chr2:128192856-128195153:+LGGEERT_cells_CD4_memory_resting1.3337e-04-0.1664image
ENSG00000136731.11,UGGT1LGGEAGT_cells_CD4_memory_resting8.3896e-05-0.1710image
chr2:128191555-128191830:+LIHCEERMacrophages_M09.4274e-030.3083image
chr2:128192856-128195153:+LIHCEERT_cells_follicular_helper1.8269e-03-0.1626image
ENSG00000136731.11,UGGT1LIHCEAGT_cells_follicular_helper1.5503e-03-0.1651image
chr2:128192856-128195153:+LUADEERDendritic_cells_resting3.8127e-040.1569image
ENSG00000136731.11,UGGT1LUADEAGDendritic_cells_resting4.3635e-040.1552image
chr2:128191555-128191830:+LUSCEERT_cells_gamma_delta4.6167e-040.3759image
chr2:128192856-128195153:+LUSCEERMacrophages_M22.2434e-040.1648image
ENSG00000136731.11,UGGT1LUSCEAGMacrophages_M28.8617e-040.1487image
chr2:128192856-128195153:+MESOEERNK_cells_activated3.7856e-03-0.3164image
ENSG00000136731.11,UGGT1MESOEAGT_cells_CD4_memory_activated4.0746e-030.3140image
chr2:128192856-128195153:+OVEERT_cells_CD83.1669e-030.1745image
ENSG00000136731.11,UGGT1OVEAGT_cells_CD85.2313e-030.1650image
chr2:128192856-128195153:+PAADEERPlasma_cells4.5463e-030.2124image
ENSG00000136731.11,UGGT1PAADEAGB_cells_naive3.8246e-030.2164image
chr2:128192856-128195153:+PCPGEERT_cells_regulatory_(Tregs)4.0494e-03-0.2156image
ENSG00000136731.11,UGGT1PCPGEAGT_cells_regulatory_(Tregs)3.8586e-03-0.2168image
chr2:128191555-128191830:+PRADEERT_cells_regulatory_(Tregs)2.4065e-020.1913image
chr2:128192856-128195153:+PRADEERT_cells_CD4_naive4.8137e-070.2239image
ENSG00000136731.11,UGGT1PRADEAGT_cells_CD4_naive2.6185e-070.2289image
chr2:128192856-128195153:+READEERDendritic_cells_resting4.3512e-030.2916image
ENSG00000136731.11,UGGT1READEAGDendritic_cells_resting3.9787e-030.2944image
chr2:128192856-128195153:+SARCEERT_cells_CD81.3074e-02-0.1555image
ENSG00000136731.11,UGGT1SARCEAGT_cells_CD81.6578e-02-0.1502image
chr2:128192856-128195153:+STADEERT_cells_CD83.5074e-030.1524image
ENSG00000136731.11,UGGT1STADEAGT_cells_CD82.2820e-030.1588image
chr2:128192856-128195153:+TGCTEERNK_cells_activated2.3116e-02-0.1842image
ENSG00000136731.11,UGGT1TGCTEAGNK_cells_activated2.1707e-02-0.1861image
chr2:128192856-128195153:+THCAEERMacrophages_M13.6954e-02-0.0931image
ENSG00000136731.11,UGGT1THCAEAGT_cells_gamma_delta4.0115e-020.0916image
chr2:128191555-128191830:+UCECEERMacrophages_M21.9568e-030.5122image
chr2:128192856-128195153:+UCECEERT_cells_follicular_helper3.2148e-02-0.1621image
ENSG00000136731.11,UGGT1UCECEAGT_cells_follicular_helper4.3574e-02-0.1528image


Top

6. Enriched editing regions and immune gene sets for UGGT1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr2:128192856-128195153:+PRADEER1.1571e-03-0.14562.9001e-03-0.13369.4347e-07-0.21839.6955e-03-0.1161image
ENSG00000136731.11,UGGT1PRADEAG2.9784e-03-0.13322.7453e-03-0.13431.0847e-06-0.21718.3436e-03-0.1184image
chr2:128192856-128195153:+THYMEER4.6693e-02-0.18674.9845e-02-0.18422.1265e-06-0.42731.9967e-02-0.2177image
ENSG00000136731.11,UGGT1UCECEAG2.5949e-04-0.27285.6685e-04-0.25804.4890e-07-0.37054.1339e-02-0.1544image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000136731.11,UGGT1ACCGSVA_HALLMARK_SPERMATOGENESISEAG2.1932e-020.2839image
chr2:128192856-128195153:+ACCGSVA_HALLMARK_SPERMATOGENESISEER4.1196e-020.2560image
ENSG00000136731.11,UGGT1BLCAGSVA_HALLMARK_HEME_METABOLISMEAG8.3471e-06-0.2224image
chr2:128191555-128191830:+BLCAGSVA_HALLMARK_APICAL_JUNCTIONEER1.5328e-02-0.3315image
chr2:128192856-128195153:+BLCAGSVA_HALLMARK_HEME_METABOLISMEER1.2195e-05-0.2184image
chr2:128192856-128195153:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.9090e-04-0.2041image
ENSG00000136731.11,UGGT1CESCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG5.2564e-04-0.1997image
chr2:128192856-128195153:+CHOLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.7952e-02-0.3978image
ENSG00000136731.11,UGGT1CHOLGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.2272e-02-0.3853image
ENSG00000136731.11,UGGT1COADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG7.8199e-05-0.2367image
chr2:128191555-128191830:+COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.9855e-03-0.3770image
chr2:128192856-128195153:+COADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER9.7520e-05-0.2336image
ENSG00000136731.11,UGGT1DLBCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.7014e-02-0.3019image
chr2:128192856-128195153:+DLBCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.4300e-02-0.3062image
ENSG00000136731.11,UGGT1ESCAGSVA_HALLMARK_HYPOXIAEAG1.2830e-030.2516image
chr2:128192856-128195153:+ESCAGSVA_HALLMARK_HYPOXIAEER4.0411e-030.2254image
ENSG00000136731.11,UGGT1GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.1230e-02-0.1601image
chr2:128192856-128195153:+GBMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.3053e-02-0.1780image
ENSG00000136731.11,UGGT1HNSCGSVA_HALLMARK_NOTCH_SIGNALINGEAG4.4725e-03-0.1278image
chr2:128192856-128195153:+HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER8.7523e-03-0.1181image
ENSG00000136731.11,UGGT1KICHGSVA_HALLMARK_GLYCOLYSISEAG1.4813e-03-0.3921image
chr2:128192856-128195153:+KICHGSVA_HALLMARK_GLYCOLYSISEER2.6472e-03-0.3724image
chr2:128192856-128195153:+KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.6318e-040.1862image
ENSG00000136731.11,UGGT1KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.3653e-040.1944image
ENSG00000136731.11,UGGT1KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.4985e-08-0.3227image
chr2:128192856-128195153:+KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0381e-07-0.3087image
ENSG00000136731.11,UGGT1LAMLGSVA_HALLMARK_UV_RESPONSE_UPEAG4.6652e-020.1644image
chr2:128192856-128195153:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER3.4453e-05-0.1802image
ENSG00000136731.11,UGGT1LGGGSVA_HALLMARK_G2M_CHECKPOINTEAG5.2706e-05-0.1757image
chr2:128192856-128195153:+LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.9924e-03-0.1436image
ENSG00000136731.11,UGGT1LIHCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG6.2565e-03-0.1429image
ENSG00000136731.11,UGGT1LUADGSVA_HALLMARK_P53_PATHWAYEAG3.8138e-060.2030image
chr2:128192856-128195153:+LUADGSVA_HALLMARK_P53_PATHWAYEER1.4213e-060.2118image
ENSG00000136731.11,UGGT1LUSCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.7285e-040.1488image
chr2:128192856-128195153:+LUSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER5.9339e-040.1535image
chr2:128192856-128195153:+MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.9697e-020.2571image
ENSG00000136731.11,UGGT1MESOGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.0590e-020.2554image
chr2:128192856-128195153:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.4652e-04-0.2159image
ENSG00000136731.11,UGGT1OVGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.7952e-04-0.2201image
ENSG00000136731.11,UGGT1PAADGSVA_HALLMARK_DNA_REPAIREAG4.7090e-03-0.2115image
chr2:128192856-128195153:+PAADGSVA_HALLMARK_DNA_REPAIREER3.2096e-03-0.2203image
chr2:128192856-128195153:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.7462e-04-0.2465image
ENSG00000136731.11,UGGT1PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.2965e-04-0.2474image
chr2:128191555-128191830:+PRADGSVA_HALLMARK_HEME_METABOLISMEER2.7050e-03-0.2526image
ENSG00000136731.11,UGGT1PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG2.6439e-11-0.2937image
chr2:128192856-128195153:+PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.8339e-10-0.2814image
ENSG00000136731.11,UGGT1READGSVA_HALLMARK_GLYCOLYSISEAG2.2874e-02-0.2346image
chr2:128192856-128195153:+READGSVA_HALLMARK_GLYCOLYSISEER2.1589e-02-0.2368image
ENSG00000136731.11,UGGT1SARCGSVA_HALLMARK_PEROXISOMEEAG1.5697e-04-0.2350image
chr2:128192856-128195153:+SARCGSVA_HALLMARK_PEROXISOMEEER7.2924e-05-0.2462image
chr2:128191555-128191830:+SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.2279e-02-0.3386image
ENSG00000136731.11,UGGT1SKCMGSVA_HALLMARK_UV_RESPONSE_UPEAG2.3583e-02-0.1051image
ENSG00000136731.11,UGGT1STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.6266e-02-0.1254image
chr2:128192856-128195153:+STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.6943e-02-0.1158image
chr2:128192856-128195153:+TGCTGSVA_HALLMARK_DNA_REPAIREER6.6873e-03-0.2191image
ENSG00000136731.11,UGGT1TGCTGSVA_HALLMARK_DNA_REPAIREAG4.2439e-03-0.2307image
chr2:128192856-128195153:+THCAGSVA_HALLMARK_PEROXISOMEEER1.4576e-05-0.1922image
ENSG00000136731.11,UGGT1THCAGSVA_HALLMARK_PEROXISOMEEAG7.3159e-05-0.1761image
chr2:128192856-128195153:+THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.5151e-04-0.3365image
ENSG00000136731.11,UGGT1THYMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6302e-04-0.3355image
ENSG00000136731.11,UGGT1UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.7284e-06-0.3460image
chr2:128192856-128195153:+UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER6.8018e-06-0.3328image
chr2:128191555-128191830:+UCECGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.3414e-03-0.5046image
chr2:128192856-128195153:+UCSGSVA_HALLMARK_ANGIOGENESISEER3.7136e-020.2792image
ENSG00000136731.11,UGGT1UCSGSVA_HALLMARK_ANGIOGENESISEAG3.6551e-020.2801image
chr2:128192856-128195153:+UVMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.1598e-020.2846image
ENSG00000136731.11,UGGT1UVMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.2797e-020.2821image


Top

7. Enriched editing regions and drugs for UGGT1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr2:128192856-128195153:+ACCBosutinibEER4.5328e-020.2511image
chr2:128192856-128195153:+BLCAAZD6244EER1.7348e-03-0.1573image
ENSG00000136731.11,UGGT1BLCAAZD6482EAG1.0914e-030.1639image
ENSG00000136731.11,UGGT1BRCAKIN001.135EAG5.8375e-030.0838image
chr2:128192856-128195153:+BRCAFTI.277EER1.7646e-020.0722image
chr2:128192856-128195153:+CESCDMOGEER1.4952e-040.2179image
ENSG00000136731.11,UGGT1CESCDMOGEAG3.2656e-040.2068image
chr2:128192856-128195153:+CHOLGefitinibEER3.8666e-02-0.3510image
ENSG00000136731.11,UGGT1CHOLGefitinibEAG3.6422e-02-0.3549image
ENSG00000136731.11,UGGT1COADCCT007093EAG3.2178e-04-0.2161image
chr2:128191555-128191830:+COADIPA.3EER1.3308e-03-0.4049image
chr2:128192856-128195153:+COADCCT007093EER5.6417e-04-0.2074image
ENSG00000136731.11,UGGT1DLBCLapatinibEAG5.1645e-030.3974image
chr2:128192856-128195153:+DLBCLapatinibEER5.2059e-030.3970image
chr2:128192856-128195153:+ESCAKU.55933EER4.5837e-04-0.2739image
ENSG00000136731.11,UGGT1ESCAAMG.706EAG1.7230e-04-0.2927image
ENSG00000136731.11,UGGT1GBMABT.888EAG3.5615e-020.1647image
chr2:128192856-128195153:+GBMKIN001.135EER1.4477e-020.1912image
chr2:128192856-128195153:+HNSCBosutinibEER2.6568e-06-0.2107image
chr2:128191555-128191830:+HNSCCyclopamineEER2.0850e-020.2242image
ENSG00000136731.11,UGGT1HNSCAZD6244EAG2.5344e-05-0.1888image
ENSG00000136731.11,UGGT1KIRCBicalutamideEAG9.6055e-04-0.1687image
chr2:128192856-128195153:+KIRCBicalutamideEER1.0494e-03-0.1675image
ENSG00000136731.11,UGGT1KIRPGDC.0449EAG5.3801e-07-0.2917image
chr2:128192856-128195153:+KIRPGDC.0449EER1.0438e-06-0.2845image
ENSG00000136731.11,UGGT1LAMLAICAREAG4.6312e-030.2323image
chr2:128192856-128195153:+LAMLAS601245EER3.7219e-030.2378image
chr2:128192856-128195153:+LGGJNK.Inhibitor.VIIIEER1.8254e-030.1361image
ENSG00000136731.11,UGGT1LGGJNK.Inhibitor.VIIIEAG2.6112e-030.1312image
ENSG00000136731.11,UGGT1LIHCA.770041EAG5.6049e-040.1901image
chr2:128192856-128195153:+LIHCA.770041EER3.0226e-040.1989image
ENSG00000136731.11,UGGT1LUADBMS.509744EAG1.2153e-05-0.1924image
chr2:128192856-128195153:+LUADBMS.509744EER3.2698e-06-0.2046image
ENSG00000136731.11,UGGT1LUSCDasatinibEAG1.3679e-04-0.1706image
chr2:128191555-128191830:+LUSCCMKEER2.3371e-04-0.3934image
chr2:128192856-128195153:+LUSCCisplatinEER3.6859e-04-0.1591image
chr2:128192856-128195153:+MESOCisplatinEER2.4220e-04-0.3948image
ENSG00000136731.11,UGGT1MESOCisplatinEAG4.3135e-04-0.3799image
chr2:128192856-128195153:+OVImatinibEER3.5932e-050.2426image
ENSG00000136731.11,UGGT1OVEmbelinEAG2.5630e-050.2466image
chr2:128192856-128195153:+PAADCI.1040EER1.5039e-03-0.2368image
ENSG00000136731.11,UGGT1PAADCI.1040EAG3.7084e-03-0.2171image
ENSG00000136731.11,UGGT1PCPGBosutinibEAG1.0642e-03-0.2447image
chr2:128192856-128195153:+PCPGBosutinibEER1.3797e-03-0.2393image
ENSG00000136731.11,UGGT1PRADAZD6482EAG2.5776e-120.3080image
chr2:128191555-128191830:+PRADBMS.509744EER6.1627e-07-0.4080image
chr2:128192856-128195153:+PRADAZD6482EER3.0275e-100.2784image
chr2:128192856-128195153:+READGDC.0449EER2.4036e-02-0.2327image
ENSG00000136731.11,UGGT1READGDC.0449EAG2.5591e-02-0.2302image
ENSG00000136731.11,UGGT1SARCATRAEAG1.4855e-040.2358image
chr2:128192856-128195153:+SARCATRAEER1.8844e-040.2322image
ENSG00000136731.11,UGGT1SKCMIPA.3EAG1.1667e-03-0.1503image
chr2:128191555-128191830:+SKCMBMS.536924EER8.1372e-04-0.4461image
chr2:128192856-128195153:+SKCMIPA.3EER3.2617e-03-0.1363image
ENSG00000136731.11,UGGT1STADAZ628EAG1.3157e-02-0.1293image
chr2:128192856-128195153:+STADKU.55933EER1.4380e-02-0.1282image
ENSG00000136731.11,UGGT1TGCTA.443654EAG8.6412e-030.2123image
chr2:128192856-128195153:+TGCTA.443654EER1.2234e-020.2028image
chr2:128192856-128195153:+THCAElesclomolEER3.6760e-06-0.2049image
ENSG00000136731.11,UGGT1THCAElesclomolEAG1.2863e-06-0.2141image
ENSG00000136731.11,UGGT1THYMJNK.Inhibitor.VIIIEAG1.5863e-050.3923image
chr2:128192856-128195153:+THYMJNK.Inhibitor.VIIIEER1.2425e-050.3967image
ENSG00000136731.11,UGGT1UCECJNK.9LEAG6.0137e-070.3667image
chr2:128191555-128191830:+UCECABT.263EER1.3929e-04-0.6074image
chr2:128192856-128195153:+UCECJNK.9LEER1.0341e-060.3594image
chr2:128192856-128195153:+UCSImatinibEER1.2930e-02-0.3302image
ENSG00000136731.11,UGGT1UCSImatinibEAG1.7310e-02-0.3169image
chr2:128192856-128195153:+UVMCisplatinEER1.8066e-030.3798image
ENSG00000136731.11,UGGT1UVMCisplatinEAG2.0846e-030.3750image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType